Literature DB >> 11960315

Regression of tumors by IFN-alpha electroporation gene therapy and analysis of the responsible genes by cDNA array.

S Li1, X Xia, X Zhang, J Suen.   

Abstract

The key to success with nonviral gene therapy as a treatment for cancer is to discover effective therapeutic genes and gene delivery methods and to understand how tumors are eradicated. We discovered that electroporation of IFN-alpha DNA into tumors in the SCCVII tumor-bearing mice led to tumor eradication in 50% of the mice and a more than two-fold increase in survival time when compared with controls (P = 0.0012). Analyses using cDNA array and Northern blot indicated that the genes responsible for the therapeutic effect of electro-IFN-alpha gene therapy included IRF-7, Granzyme A, Granzyme C, Gjb2, Krt14, Mig, IP-10 and MCP3. Because most of these genes have been known to either inhibit angiogenesis (Mig, IP-10), inhibit tumor growth (Gjb2, MCP3), kill tumor cells (Granzyme A and C), or induce expression of antitumor gene (IRF-7), they may become promising therapeutic gene candidates for a combination gene therapy approach to cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960315     DOI: 10.1038/sj.gt.3301645

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

1.  Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment.

Authors:  P Xiao; Y Guo; H Zhang; X Zhang; H Cheng; Q Cao; Y Ke
Journal:  Oncogene       Date:  2018-05-24       Impact factor: 9.867

2.  Interleukin-30: a novel antiinflammatory cytokine candidate for prevention and treatment of inflammatory cytokine-induced liver injury.

Authors:  Denada Dibra; Jeffry Cutrera; Xueqing Xia; Bhaskar Kallakury; Lopa Mishra; Shulin Li
Journal:  Hepatology       Date:  2012-03-01       Impact factor: 17.425

3.  Optimization of a plasma facilitated DNA delivery method.

Authors:  Richard J Connolly; Andrew M Hoff; Richard Gilbert; Mark J Jaroszeski
Journal:  Bioelectrochemistry       Date:  2014-10-13       Impact factor: 5.373

4.  IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors.

Authors:  Shiguo Zhu; Dean Anthony Lee; Shulin Li
Journal:  J Immunol       Date:  2010-02-05       Impact factor: 5.422

5.  CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors.

Authors:  Jiemiao Hu; Shiguo Zhu; Xueqing Xia; Liangfang Zhang; Eugenie S Kleinerman; Shulin Li
Journal:  Mol Cancer       Date:  2014-02-24       Impact factor: 27.401

Review 6.  CXCL9: evidence and contradictions for its role in tumor progression.

Authors:  Qiang Ding; Panpan Lu; Yujia Xia; Shuping Ding; Yuhui Fan; Xin Li; Ping Han; Jingmei Liu; Dean Tian; Mei Liu
Journal:  Cancer Med       Date:  2016-10-10       Impact factor: 4.452

Review 7.  The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

Authors:  Muireann T Kelleher; Gilbert Fruhwirth; Gargi Patel; Enyinnaya Ofo; Frederic Festy; Paul R Barber; Simon M Ameer-Beg; Borivoj Vojnovic; Cheryl Gillett; Anthony Coolen; György Kéri; Paul A Ellis; Tony Ng
Journal:  Target Oncol       Date:  2009-09-16       Impact factor: 4.493

8.  COTRASIF: conservation-aided transcription-factor-binding site finder.

Authors:  Bogdan Tokovenko; Rostyslav Golda; Oleksiy Protas; Maria Obolenskaya; Anna El'skaya
Journal:  Nucleic Acids Res       Date:  2009-03-05       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.